{
  "source": "PA-Notification-Solaraze.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1159-9\nProgram Prior Authorization – Notification\nMedication Solaraze (diclofenac 3% gel)\nP&T Approval Date 8/2015, 7/2016, 7/2018, 7/2019, 7/2020, 7/2021, 7/2022, 7/2023, 7/2024\nEffective Date 10/1/2024\n1. Background:\nSolaraze (diclofenac 3% topical gel) is indicated for the topical treatment of actinic keratosis\n(AK). The recommended duration of therapy is from 60 to 90 days.\n2. Coverage Criteriaa:\nA. Authorization\n1. Solaraze (diclofenac 3% topical gel)* will be approved based on the following criterion:\na. Diagnosis of actinic keratosis\nAuthorization will be issued for 3 months\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n*Applies to brand and generic Solaraze.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n4. References:\n1. Diclofenac 3% topical gel (generic Solaraze) [package insert]. Bedminster, NJ: Alembic\nPharmaceuticals Limited; March 2023.\n© 2024 United HealthCare Services, Inc.\n1\nProgram Solaraze Prior Authorization – Notification\nChange Control\nDate Change\n8/2015 New program.\n7/2016 Updated references.\n7/2018 Annual review. No changes.\n7/2019 Annual review. No changes.\n7/2020 Annual review. No changes.\n7/2021 Annual review. Added state mandate language.\n7/2022 Annual review. Updated references.\n7/2023 Annual review. Added generic name due to brand unavailable. Updated\nreferences.\n7/2024 Annual review. Updated references.\n© 2024 United HealthCare Services, Inc.\n2"
  ]
}